| Identification | Back Directory | [Name]
2-Chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-benzenepropanaminehydrochloride | [CAS]
177172-49-5 | [Synonyms]
R-568
R 568 hydrochloride
Tecalcet (Hydrochloride)
R-568 hydrochloride >=95% (HPLC)
2-Chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-benzenepropanaminehydrochloride
(R)-3-(2-Chlorophenyl)-N-(1-(3-methoxyphenyl)ethyl)propan-1-amine hydrochloride
3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine, hydrochloride
Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-, hydrochloride (1:1) | [Molecular Formula]
C18H23Cl2NO | [MDL Number]
MFCD16038895 | [MOL File]
177172-49-5.mol | [Molecular Weight]
340.287 |
| Chemical Properties | Back Directory | [Melting point ]
183.3-184.4 °C | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
DMSO : 50 mg/mL (146.93 mM; Need ultrasonic) | [form ]
Powder | [color ]
White to off-white | [Optical Rotation]
[α]/D +35 to +40°, c =0.5 in chloroform-d |
| Hazard Information | Back Directory | [Description]
Calcium-sensing receptor (CaSR) is a G protein-coupled receptor that is involved in calcium homeostasis. Activation of CaSR on parathyroid cells decreases the secretion of parathyroid hormone (PTH), which in turn reduces blood calcium concentration. R-568 is a calcimimetic compound that can allosterically activate or positively modulate the human CaSR. It dose-dependently decreases circulating levels of PTH in both normal individuals and patients with primary hyperparathyroidism in clinical trials. R-568 is used in research to explore novel actions of CaSR. | [Uses]
Treatment of hyperparathyroidism and related disorders,
such as hypercalcemia (reduction of PTH secretion
through modulation of calcium ion receptors on parathyroid
cells). | [Brand name]
Norcalcin (Amgen). | [in vivo]
Tecalcet (1.5 and 15 mg/kg, orally, twice daily for 4 days) inhibits PT cell proliferation in rats with renal insufficiency[1]. | Animal Model: | 10-wk-old Male Sprague-Dawley rats weighing 310-350 g[1]. | | Dosage: | 1.5 and 15 mg/kg. | | Administration: | Orally twice daily for 4 days. | | Result: | Did not significantly change serum 1,25 (OH)2D3 levels. In contrast, serum PTH levels were reduced by in a dose-dependent manner.
Clearly reduced the number of BrdU-positive PT cells by 20% at a low dose (1.5 mg/kg body wt), and by 50% at a high dose (15 mg/kg body wt), indicating an antiproliferative effect on PT cells.
Reduced PT cell volume in a dose-dependent manner.
|
| [storage]
Store at -20°C | [References]
[1] E F NEMETH. Calcimimetics with potent and selective activity on the parathyroid calcium receptor.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95 7: 4040-4045. DOI: 10.1073/pnas.95.7.4040
[2] J FOX. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.[J]. Journal of Pharmacology and Experimental Therapeutics, 1999, 290 2: 473-479.
[3] M WADA. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.[J]. Journal of Clinical Investigation, 1997, 100 12: 2977-2983. DOI: 10.1172/jci119851 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|